Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669890 · ClinicalTrials.gov registry record · Phase 1
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
A Phase 1 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00669890: Clinical Trial Phase 1 study, sponsored by New York Medical College.
NCT00669890 is a Phase 1 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00669890, a Phase 1 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this study for allogeneic stem cell transplant. (Part A)
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Gemtuzumab Ozogamicin
- DRUG Thymoglobulin
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Why NCT00669890 stopped before completion
NCT00669890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00669890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00669890 about?
NCT00669890 is a clinical study titled "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML". The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given i...
What is the current status of trial NCT00669890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00669890?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Gemtuzumab Ozogamicin (DRUG), Thymoglobulin (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00669890?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00669890's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia